Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares were up 7.8% on Thursday . The stock traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Trading Up 7.8 %
The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average price of $0.19 and a two-hundred day moving average price of $0.19.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Featured Stories
- Five stocks we like better than Vyant Bio
- How to Use the MarketBeat Stock Screener
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- What Are Treasury Bonds?
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
